Bernard Gilly
Founder en PIXIUM VISION .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Alexia Perouse | F | - |
iBionext SAS
iBionext SAS Investment ManagersFinance iBionext SAS (iBionext) is an independent venture capital firm headquartered in Paris, France. The firm was founded in 2012 by Christophe Bancel and Alexia Perouse.
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France.
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | 9 años |
Michael Wyzga | M | 69 | 11 años | |
Soad El Ghazouani | F | - |
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | 6 años |
Laurence Rodriguez | F | 56 | 3 años | |
Edouard Gasser | M | - |
Tilak Healthcare SAS
Tilak Healthcare SAS Information Technology ServicesTechnology Services Tilak Healthcare SAS develops platform of serious medical games. It enables diagnostic and therapy of ophthalmologic diseases through early detection and self-tracking. The company was founded in 2016 and is headquartered in Paris, France. | 7 años |
Laurent Farcy | M | 51 |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | 16 años |
Magali Taiel | M | - | 6 años | |
Luca Verre | M | 43 |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | 10 años |
Elsy Boglioli Hofman | F | 42 | 4 años | |
Françoise de Craecker | F | 62 | 3 años | |
Dietrick Wolf | M | - |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | 10 años |
Lloyd Diamond | M | 57 | 5 años | |
Christophe Bancel | M | - |
iBionext SAS
iBionext SAS Investment ManagersFinance iBionext SAS (iBionext) is an independent venture capital firm headquartered in Paris, France. The firm was founded in 2012 by Christophe Bancel and Alexia Perouse. | 12 años |
Maritza McIntyre | M | 58 | 5 años | |
Robert J. W. ten Hoedt | M | 64 | 8 años | |
Chahra Khaoua Epouse Louafi | F | 53 |
Brainever SAS
Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | - |
Alain Prochiantz | M | - |
Brainever SAS
Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | - |
Gérard Hascoët | M | 74 |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 20 años |
Philippe Chapuis | M | 56 |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | 16 años |
Benoît Habert | M | 59 | 24 años | |
Sarah Sorrel | F | - |
T-Heart SAS
T-Heart SAS Miscellaneous Commercial ServicesCommercial Services T-Heart SAS is an investment holding company with interest in research and development services on natural sciences sector. The company was founded on December 06, 2018 and is headquartered in Paris, France. | 2 años |
Marie Meynadier | M | 63 | 6 años | |
Simone Seiter | M | 57 | 7 años | |
Ingolf Held | M | - |
Grai Matter Labs SAS
Grai Matter Labs SAS Information Technology ServicesTechnology Services Grai Matter Labs SAS provides computer programming services. The company was founded on May 9, 2016 and is headquartered in Paris, France. | - |
Maximilien Fournier Sourdille | M | 35 |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | - |
Laurent Vandebrouck | M | - |
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | - |
Julio Benedicto | M | - | 7 años | |
Marion Ghibaudo | M | - | 3 años | |
Florent Aptel | M | - |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | - |
Sissel Rodahl | F | - | 2 años | |
Scott Jeffers | M | - | 2 años | |
Dimitri Boulanger | M | - |
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | - |
Olivia Le Proux de la Rivière | F | - | 16 años | |
Alexandre Loiseau | M | - |
Tilak Healthcare SAS
Tilak Healthcare SAS Information Technology ServicesTechnology Services Tilak Healthcare SAS develops platform of serious medical games. It enables diagnostic and therapy of ophthalmologic diseases through early detection and self-tracking. The company was founded in 2016 and is headquartered in Paris, France. | 3 años |
Cedric Sellin | M | - |
Tilak Healthcare SAS
Tilak Healthcare SAS Information Technology ServicesTechnology Services Tilak Healthcare SAS develops platform of serious medical games. It enables diagnostic and therapy of ophthalmologic diseases through early detection and self-tracking. The company was founded in 2016 and is headquartered in Paris, France. | 6 años |
Ralf Hornig | M | - | 12 años | |
Muriel Badawi | F | - |
iBionext SAS
iBionext SAS Investment ManagersFinance iBionext SAS (iBionext) is an independent venture capital firm headquartered in Paris, France. The firm was founded in 2012 by Christophe Bancel and Alexia Perouse. | - |
Bernard Chauvin | M | 70 |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | 11 años |
August Moretti | M | 73 | 2 años | |
Bruno Cervera | M | - |
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | - |
Bernard Daugeras | M | - |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | - |
Cedric Sellin | M | - |
Tilak Healthcare SAS
Tilak Healthcare SAS Information Technology ServicesTechnology Services Tilak Healthcare SAS develops platform of serious medical games. It enables diagnostic and therapy of ophthalmologic diseases through early detection and self-tracking. The company was founded in 2016 and is headquartered in Paris, France. | 6 años |
Alain Benisty | M | 64 |
PX Therapeutics SA
PX Therapeutics SA Miscellaneous Commercial ServicesCommercial Services PX Therapeutics SA manufactures and develops recombinant proteins and monoclonal antibodies. Its services include protein engineering, optimization of drug candidates, humanization of antibodies, and production and release of GMP batches for clinical studies. The firm specializes in the field of in-vivo and in-vitro diagnostics, industrial enzymes, and ancillary products. The company was founded by Tristan Rousselle and Nicolas Mouz in November 2000 and is headquartered in Grenoble, France. | - |
Anja Krammer | F | 56 | 2 años | |
Cédric Moreau | M | 37 | 5 años | |
Tao Wu | M | - |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | 9 años |
Karine Chevrie | M | - | 9 años | |
Offer Nonhoff | M | - | 3 años | |
Donald Jones | M | - |
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | - |
Mounia Chaoui-Roulleau | M | 52 |
Eye Tech Care SA
Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | 10 años |
Eric Rougemond | M | 55 |
PX Therapeutics SA
PX Therapeutics SA Miscellaneous Commercial ServicesCommercial Services PX Therapeutics SA manufactures and develops recombinant proteins and monoclonal antibodies. Its services include protein engineering, optimization of drug candidates, humanization of antibodies, and production and release of GMP batches for clinical studies. The firm specializes in the field of in-vivo and in-vitro diagnostics, industrial enzymes, and ancillary products. The company was founded by Tristan Rousselle and Nicolas Mouz in November 2000 and is headquartered in Grenoble, France. | 11 años |
Vanessa Giraud | F | 50 | - | |
Donald Jones | M | - |
Chronolife SAS
Chronolife SAS Miscellaneous Commercial ServicesCommercial Services Chronolife SAS engages in the research and development activity in natural sciences. The company is headquartered in Paris, France. | 6 años |
Brian Burg | M | - | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
José-Alain Sahel | M | 68 | - | |
Bernard Davitian | M | 64 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 10 años |
Alessio Beverina | M | - |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 10 años |
Jean-Philippe Alex Combal | M | 58 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 5 años |
Nitza Thomasson-Perret | M | 51 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | - |
Khalid Ishaque | M | - | 5 años | |
Arnaud Fayet | M | 83 | - | |
Peter Goodfellow | M | 72 | 9 años | |
Ryad Benosman | M | - |
Grai Matter Labs SAS
Grai Matter Labs SAS Information Technology ServicesTechnology Services Grai Matter Labs SAS provides computer programming services. The company was founded on May 9, 2016 and is headquartered in Paris, France.
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | - |
Maïlys Ferrère | F | 60 | 4 años | |
Barrett Katz | M | 74 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 5 años |
Natalie Mount | M | - | 4 años | |
Christoph Posch | M | - |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | - |
Serge Picaud | M | 63 | - | |
Rafaèle Elisabeth Tordjman | M | 54 |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 16 años |
Pierre Marc Bélichard | M | 63 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | - |
Antoine Papiernik | M | 56 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 9 años |
André-Michel Ballester | M | 65 | - | |
James A. Reinstein | M | 59 | - | |
Isabelle Scarabin | F | - | 8 años | |
Philippe Motté | M | 64 | - | |
Leigh Shaw | M | - | 2 años | |
Atul Sinha | M | - |
Grai Matter Labs SAS
Grai Matter Labs SAS Information Technology ServicesTechnology Services Grai Matter Labs SAS provides computer programming services. The company was founded on May 9, 2016 and is headquartered in Paris, France. | - |
Sio-Hoi Leng | M | - |
Grai Matter Labs SAS
Grai Matter Labs SAS Information Technology ServicesTechnology Services Grai Matter Labs SAS provides computer programming services. The company was founded on May 9, 2016 and is headquartered in Paris, France. | - |
Mohamed Genead | M | - | - | |
Clothilde Caillet | M | - | - | |
Thomas Gidoin | M | 41 | 9 años | |
Philippe Bergonzo | M | - | - | |
Isabelle Pengue-Koyi | M | - | 6 años | |
Margaret Liu | M | 66 | 6 años | |
Jean François Carmier | M | - | - | |
Botond Roska | M | 54 | - | |
Catherine Mathis | M | 58 | 20 años | |
Laurence Bertaud | F | 54 | - | |
Nicolas Autret | M | 43 |
Prophesee SA
Prophesee SA Medical SpecialtiesHealth Technology Prophesee SA engages in the development of neuromorphic vision systems. The firm serves clients in autonomous vehicles, industrial automation, IoT, and security and surveillance. The company was founded by Christoph Posch, Ryad Benosman, Luca Verre, and Bernard Jacques Alex Gilly in 2014 and is headquartered in Paris, France. | 2 años |
Robert J. Hill | M | - | - | |
Harvey N. Masonson | M | - | 1 años | |
Guido Magni | M | 70 | 6 años | |
Didier Laurens | M | 59 | - | |
Didier Pruneau | M | 68 | 5 años | |
Genghis Lloyd-Harris | M | 67 | 5 años | |
Florent Gros | M | 56 | - | |
Gary Jay Sternberg | M | - |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | - |
Thierry Léveillard | M | - |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | - |
Jean Schmitt | M | 59 |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 10 años |
Jean Bennett | M | - | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Francia | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Bernard Gilly
- Red Personal